Interim report, foreign filer
Open the filing on sec.gov
Virax Biolabs Group Limited (VRAX)
Nasdaq: VRAX · In Vitro & In Vivo Diagnostic Substances · Lanarkshire, GB · filing with the SEC since 2021
The companyfiscal 2025, as filed
Revenue$6331.00-96.0%
Net income-$6.1M+10.0%
Earnings per share$-1.62+51.8%
Operating cash flow-$4.6M+26.9%
Cash$4.2M+17.8%
Debtn/a
Shareholders’ equity$5.5M+6.3%
Shares, diluted3,730,347+85.9%
Return on equity-111.1%
The recordfrom its filings
Filings in 202632
Newest filingOct 29 · 6-K
Annual reportJul 6, 2026
Quarterly reportn/a
Next report due20-F by Jul 29
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Insider holding, initial
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Shelf offering
Open the filing on sec.gov
Registration effective
Open the filing on sec.gov
Shelf registration, foreign filer, amended
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.